A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon‐alpha2

A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon‐alpha2

Abstract Background Conventional cytoreductive therapy for patients with chronic Philadelphia‐negative myeloproliferative neoplasms (MPNs) includes hydroxyurea (HU), interferon‐alpha2 (IFN), and anagrelide. HU is worldwide the most used cytoreductive agent, which lowers elevated blood cell counts wi...

Full description

Bibliographic Details
Main Authors: Marc J. B. Dam, Rasmus K. Pedersen, Trine A. Knudsen, Morten Andersen, Christina Ellervik, Morten Kranker Larsen, Lasse Kjær, Vibe Skov, Hans C. Hasselbalch, Johnny T. Ottesen
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Cancer Medicine
Subjects:
combination therapy
essential thrombocythemia
hydroxyurea
interferon‐alpha2
MPN
myelofibrosis
Online Access:https://doi.org/10.1002/cam4.5285

Internet

https://doi.org/10.1002/cam4.5285

Similar Items